NCT06633757View on ClinicalTrials.gov

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

October 22, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Primary Ciliary Dyskinesia (PCD)
Interventions
DRUG

RCT1100

mRNA therapy supplied as varying dose strengths administered via oral inhalation using nebulizer

Trial Locations (3)

2100

Copenhagen University Hospital - Rigshospitalet, Copenhagen

27514

UNC, Chapel Hill

48149

Münster University Hospital, Albert-Schweitzer-Campus 1, Münster

Sponsors
All Listed Sponsors
lead

ReCode Therapeutics

INDUSTRY

NCT06633757 - Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance | Biotech Hunter | Biotech Hunter